Tricida Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Tricida's estimated annual revenue is currently $10.9M per year.
- Tricida received $100.0M in venture funding in March 2018.
- Tricida's estimated revenue per employee is $58,043
- Tricida's total funding is $257M.
- Tricida has 187 Employees.
- Tricida grew their employee count by 85% last year.
- Tricida currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
|ZO Skin Health||$69.5M||346||2%||N/A||-||N/A|
What Is Tricida?
Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its late-stage investigational product candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). We are led by a management team with an accomplished and proven track record in discovering, developing and commercializing new therapeutics, with extensive experience in building successful companies around strong science and unmet medical needs. We recently completed a successful Initial Public Offering and our stock is listed on the Nasdaq Global Select Market under the symbol TCDA. We are expanding our existing group of exceptionally talented and well-motivated colleagues to develop and commercialize our first-in-class drug candidate, TRC101. Tricida's shared culture of teamwork, camaraderie and empowerment is evident in the dedication and focus our team demonstrates, with a commitment to the ultimate goal of improving and prolonging the lives of people living with CKD, and bringing critically needed new therapies to patients. Highly Competitive Compensation and Benefitskeywords:Analytics,Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--. NDA Submitted under the FDA's Accelerated Approval Program. Tricida, Inc. (TCDA), a ...
Tricida (TCDA) Announces Submission of New Drug Application for Veverimer for Treatment of Metabolic Acidosis in Patients with CKD.
Tricida Inc (NASDAQ:TCDA) VP Claire Lockey sold 10,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd.
|2017-11-09||$57.5M||D||Wellington Management Company LLP||Article|
Tricida Executive Hires
|2016-01-13||Claire Lockey||Chief Development Officer/SVP||Article|
|2017-02-16||Wilhelm Stahl||SVP/Chief Technology Officer||Article|
|2018-01-09||Jeroen van Beek||SVP & Chief Commercial Officer||Article|
|2018-08-02||Dawn Parsell||SVP Clinical Development||Article|
|2019-01-18||Susannah Cantrell||SVP/Chief Commercial Officer||Article|